@文章{info:doi/ 10.296 /37790，作者="Pickering, Gis{\ ' e}le and Mezouar, Linda and Kechemir, Hayet and ebele - bitoun, Caty"，标题="骨关节炎和腰痛患者使用扑热息痛:电子病历数据的信息流行病学研究和观察分析"，期刊="JMIR公共卫生监测"，年="2022"，月="10"，日="27"，卷="8"，数="10"，页="e37790"，关键词="骨关节炎;腰痛;一般实践;风湿病学;扑热息痛;背景:下腰痛(LBP)和骨关节炎(OA)是常见的肌肉骨骼疾病，约占全球残疾生活年数的17.0{\%};然而，缺乏关于这些条件的真实数据。扑热息痛品牌在法国经常被开用于肌肉骨骼疼痛，包括Doliprane, Dafalgan和Ixprim(曲马多-扑热息痛)。目的:本回顾性研究的目的是了解LBP或OA患者在使用扑热息痛治疗时的过程。方法:进行三项研究。 Two studies analyzed electronic medical records from general practitioners (GPs) and rheumatologists of patients with OA or LBP, who had received at least one paracetamol prescription between 2013 and 2018 in France. Data were extracted, anonymized, and stratified by gender, age, and provider specialty. The third study, an infodemiology study, analyzed associations between terms used on public medical forums and Twitter in France and the United States for OA only. Results: In the first 2 studies, among patients with LBP (98,998), most (n=92,068, 93.0{\%}) saw a GP, and Doliprane was a first-line therapy for 87.0{\%} (n=86,128) of patients (71.0{\%} [n=61,151] in combination with nonsteroidal anti-inflammatory drugs [NSAIDs] or opioids). Among patients with OA (99,997), most (n=84,997, 85.0{\%}) saw a GP, and Doliprane was a first-line therapy for 83.0{\%} (n=82,998) of patients (62.0{\%} [n=51,459] in combination). Overall, paracetamol monotherapy prescriptions decreased as episodes increased. In the third study, in line with available literature, the data confirmed that the prevalence of OA increases with age (91.5{\%} [212,875/232,650] above 41 years), OA is more predominant in females (46,530/232,650, 20.0{\%}), and paracetamol use varies between GPs and rheumatologists. Conclusions: This health surveillance analysis provides a better understanding of the journey for patients with LBP or OA. These data confirmed that although paracetamol remains the most common first-line analgesic for patients with LBP and OA, usage varies among patients and health care specialists, and there are concerns over efficacy. ", issn="2369-2960", doi="10.2196/37790", url="https://publichealth.www.mybigtv.com/2022/10/e37790", url="https://doi.org/10.2196/37790", url="http://www.ncbi.nlm.nih.gov/pubmed/363015" }